It has been documented that cholesterol levels are elevated in the tumor microenvironment of ovarian cancer patients which can upregulate the expression of the drug efflux pump proteins ABCG2 and MDR1, as well as cholesterol receptor LXRα/β to reduce the sensitivity of ovarian cancer cells to chemotherapeutic agents (31). This evidence concerns the gene ABCG2 and ovarian carcinoma.